Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Prelude Therapeutics (PRLD) Enterprise Value (2024 - 2026)

Prelude Therapeutics' Enterprise Value history spans 4 years, with the latest figure at -$144.6 million for Q1 2026.

  • On a quarterly basis, Enterprise Value fell 40.23% to -$144.6 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$144.6 million, a 40.23% decrease, with the full-year FY2025 number at -$103.2 million, up 25.02% from a year prior.
  • Enterprise Value hit -$144.6 million in Q1 2026 for Prelude Therapeutics, down from -$103.2 million in the prior quarter.
  • Over the last five years, Enterprise Value for PRLD hit a ceiling of -$58.2 million in Q3 2025 and a floor of -$237.0 million in Q4 2023.
  • Historically, Enterprise Value has averaged -$145.6 million across 4 years, with a median of -$141.1 million in 2024.
  • Biggest five-year swings in Enterprise Value: surged 63.09% in 2025 and later plummeted 40.23% in 2026.
  • Tracing PRLD's Enterprise Value over 4 years: stood at -$237.0 million in 2023, then soared by 41.91% to -$137.7 million in 2024, then rose by 25.02% to -$103.2 million in 2025, then crashed by 40.1% to -$144.6 million in 2026.
  • Business Quant data shows Enterprise Value for PRLD at -$144.6 million in Q1 2026, -$103.2 million in Q4 2025, and -$58.2 million in Q3 2025.